Painkiller ‘Meftal’ Linked to Serious Adverse Reactions, Govt Issues Warning

New Delhi: The Indian Pharmacopoeia Commission (IPC) has issued a drug safety alert urging vigilance regarding the painkiller Meftal, commonly prescribed for menstrual cramps and rheumatoid arthritis. The commission’s advisory, released on November 30, stems from a preliminary analysis of adverse drug reactions within the Pharmacovigilance Programme of India (PvPI) database.

Meftal, containing mefenamic acid, is utilized in treating conditions such as rheumatoid arthritis, osteoarthritis, dysmenorrhoea, mild to moderate pain, inflammation, fever, and dental pain. The alert specifically highlights the potential occurrence of drug reactions associated with eosinophilia and systemic symptoms (DRESS) syndrome.

Healthcare professionals and patients are strongly advised to closely monitor and report any adverse drug reactions promptly. In case of encountering such reactions, individuals are encouraged to report the matter to the national coordination centre of the PvPI through the commission’s official website (www.ipc.gov.in), the Android mobile app ADR PvPI, or the PvPI Helpline at 1800-180-3024.